Related Experiment Videos
Camptothecin analogs in malignant gliomas: comparative analysis and characterization
Prakash Sampath1, Eric Amundson, Monroe E Wall
1Department of Neurosurgery, Brown Medical School, Rhode Island Hospital, Providence, Rhode Island 02903, USA. Prakash_Sampath@hotmail.com
Journal of Neurosurgery
|March 26, 2003
Summary
New camptothecin (CPT) analogs show enhanced potency and stability for treating brain tumors. The 10,11-methylenedioxy (MD) CPT class demonstrated superior cytotoxicity, offering promise for local glioma therapy.
Area of Science:
- Oncology
- Pharmacology
- Neuro-oncology
Background:
- Camptothecin (CPT) analogs are investigated for antitumor activity against brain tumors.
- Poor bioavailability and blood-brain barrier penetration limit systemic CPT efficacy.
- Local delivery via polymers shows promise for intracranial glioma treatment.
Purpose of the Study:
- To compare and characterize novel camptothecin (CPT) analogs for potential local therapy of glioma.
- To identify CPT analogs with improved potency and stability over existing treatments.
Main Methods:
- In vitro cytotoxicity assays (clonogenic, monotetrazolium) on human and murine glioma cell lines.
- Assay to determine drug-stabilized cleavable complex formation.
- Comparison of 22 CPT analogs, including 10,11-methylenedioxy (MD) class.
Main Results:
- The 10,11-methylenedioxy (MD) class of CPT analogs exhibited the highest cytotoxicity.
- Specific MD analogs demonstrated significantly greater antiproliferative activity than CPT, Na-CPT, and BCNU.
- 10,11-MD-20(RS)-CPT induced more topoisomerase I-stabilized cleavable complexes than Na-CPT.
Conclusions:
- Novel CPT analogs, particularly the 10,11-MD class, offer enhanced potency and stability for brain tumor treatment.
- These CPT analogs are promising candidates for developing localized therapies against primary and metastatic brain tumors.